Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses.

Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses.
复制标题

DOI:
10.1016/j.cell.2018.03.038
复制
发表时间:
2018-05-31
期刊:
影响因子:
64.5
通讯作者:
Wong WW
Wong WW
中科院分区:
生物学1区
文献类型:
--
作者:
Cho JH;Collins JJ;Wong WW

文献摘要

参考文献

被引文献

相似文献

表达嵌合抗原受体(CARS)的T细胞是一种很有前途的癌症治疗药物,有望成为终极智能癌症治疗药物。为了扩展CAR T细胞的能力,我们在这里提出了一个分离的、通用的和可编程的(SUPRA)CAR系统,该系统同时包含多个关键的“升级”,例如无需重新设计T细胞就可以切换目标的能力,微调T细胞激活强度的能力,以及对多种抗原的感知和逻辑反应的能力。这些功能有助于防止复发,减轻过度激活,并增强特异性。我们针对两种不同的肿瘤模型测试我们的SUPRRA系统,以展示其广泛的实用性,并使其组件人性化,以最大限度地减少潜在的免疫原性问题。此外,我们扩展了正交超CAR系统以独立地调节不同的T细胞亚群,展示了一个双重诱导的CAR系统。总而言之,这些超级汽车表明,多种先进的逻辑和控制功能可以被实施到一个单一的集成系统中。一种嵌合抗原受体系统可以整合来自多种抗原的信号,并以细胞类型特异性的方式微调T细胞的激活,有望提高CAR T细胞治疗癌症的安全性和特异性。
T cells expressing chimeric antigen receptors (CARs) are promising cancer therapeutic agents, with the prospect of becoming the ultimate smart cancer therapeutics. To expand the capability of CAR T cells, here we present a split, universal, and programmable (SUPRA) CAR system that simultaneously encompasses multiple critical “upgrades”, such as the ability to switch targets without re-engineering the T cells, finely tune T cell activation strength, and sense and logically respond to multiple antigens. These features are useful to combat relapse, mitigate over-activation, and enhance specificity. We test our SUPRA system against two different tumor models to demonstrate its broad utility and humanize its components to minimize potential immunogenicity concerns. Furthermore, we extend the orthogonal SUPRA CAR system to regulate different T cell subsets independently, demonstrating a dually inducible CAR system. Together, these SUPRA CARs illustrate that multiple advanced logic and control features can be implemented into a single, integrated system. A chimeric antigen receptor system that can integrate signals from multiple antigens and fine tune T cell activation in a cell type-specific manner holds promises for enhancing the safety and specificity of CAR T cell therapies for cancer treatment.
DOI: 10.1158/2326-6066.cir-14-0127
发表时间: 2015-02
影响因子: 10.1
作者:
Hudecek M;Sommermeyer D;Kosasih PL;Silva-Benedict A;Liu L;Rader C;Jensen MC;Riddell SR
通讯作者: Riddell SR
T细胞共刺激和共抑制的分子机制。
DOI: 10.1038/nri3405
发表时间: 2013-04
期刊: Nature reviews. Immunology
影响因子: --
作者:
通讯作者: --
DOI: 10.1038/bcj.2016.61
发表时间: 2016-08-12
影响因子: 12.8
作者:
Cartellieri M;Feldmann A;Koristka S;Arndt C;Loff S;Ehninger A;von Bonin M;Bejestani EP;Ehninger G;Bachmann MP
通讯作者: Bachmann MP
DOI: 10.1126/scitranslmed.3005930
发表时间: 2013-03-20
影响因子: 17.1
作者:
Brentjens RJ;Davila ML;Riviere I;Park J;Wang X;Cowell LG;Bartido S;Stefanski J;Taylor C;Olszewska M;Borquez-Ojeda O;Qu J;Wasielewska T;He Q;Bernal Y;Rijo IV;Hedvat C;Kobos R;Curran K;Steinherz P;Jurcic J;Rosenblat T;Maslak P;Frattini M;Sadelain M
通讯作者: Sadelain M
DOI: 10.4161/onci.28147
发表时间: 2014
期刊: Oncoimmunology
影响因子: 7.2
作者:
Klingemann H
通讯作者: Klingemann H